Cargando…

SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?

Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder in which patients develop multiple simultaneous hormone-secreting tumors. Most common tumors include: anterior pituitary adenomas (50%), multi-gland parathyroid adenomas (95%), and gastroenteropancreatic neuroendocri...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Maya E, Sustache, Yashira M Ortega, Agarwal, Sunita Kishore, Tepede, Aisha, Mandl, Adel, Bansal, Rashika, Tirosh, Amit, Piaggi, Paolo, Weinstein, Lee Scott, Simonds, William F, Blau, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208645/
http://dx.doi.org/10.1210/jendso/bvaa046.672
_version_ 1783530894495055872
author Lee, Maya E
Sustache, Yashira M Ortega
Agarwal, Sunita Kishore
Tepede, Aisha
Mandl, Adel
Bansal, Rashika
Tirosh, Amit
Piaggi, Paolo
Weinstein, Lee Scott
Simonds, William F
Blau, Jenny
author_facet Lee, Maya E
Sustache, Yashira M Ortega
Agarwal, Sunita Kishore
Tepede, Aisha
Mandl, Adel
Bansal, Rashika
Tirosh, Amit
Piaggi, Paolo
Weinstein, Lee Scott
Simonds, William F
Blau, Jenny
author_sort Lee, Maya E
collection PubMed
description Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder in which patients develop multiple simultaneous hormone-secreting tumors. Most common tumors include: anterior pituitary adenomas (50%), multi-gland parathyroid adenomas (95%), and gastroenteropancreatic neuroendocrine tumors (40-80%). Only rare MEN1 associated glucagonomas (<1%), and ACTH-producing neuroendocrine tumors (<5%) are known to increase risk of hypercoagulability. It is unknown if patients with MEN1 syndrome have increased risk of venous thrombolytic events (VTE), defined as a deep-vein thrombosis and/or pulmonary embolism. Methods: We queried a prospective natural history study of MEN1 patients who tested positive for germline MEN1 mutations (n=287) between 1991-2019 (54 patients on our current protocol were followed before 1991; the earliest was 1971). All lifetime events of VTE were included. Search terms included: DVT, thromb, embol, PE, pulmonary embolism, clot, hematology consult, anticoagulant, coumadin, lovenox, xarelto, warfarin, aspirin, rivaroxaban and apixaban. After initial screening, 10 patients were removed due to insufficient clinical data. Kaplan-Meier analysis was performed to compare age of death between the two cohorts. Results were expressed as mean ± standard deviation. Results: Thirty-four subjects (mean 57.5 years-old, 17 women) were identified with any VTE, yielding a prevalence rate of 13.4%. The incidence of VTE corresponded to 264 events per 100,000 patient-years, which was ~2-fold higher than the estimated annual incidence rate in the general population (104-183/100,000 patient years).(1) Kaplan-Meier analysis revealed no significant difference in survival between the two groups (non-VTE cohort mean 81.1 years ± 2.23; VTE cohort mean 77.4 years ± 3.45; p = 0.96). Thirty-two events occurred during the surveillance period at our institution; 9 individuals had more than one VTE. At the time of VTE, 80% had hyperparathyroidism (mean PTH ± SD; 97.56 pg/mL ± 90.76), 21% had hyperprolactinemia (prolactin 25.7μg/L ± 43.41), 62.5% had hypergastrinemia (mean gastrin 1100.9 pg/mL ± 3127.8), and 84.6% had non-functional pancreatic neuroendocrine tumors. One patient was identified to have a Factor V Leiden mutation, 3 patients had lupus anti-coagulant. Eleven patients experienced events within a post-surgical period of 3 months. Conclusions: Hypercoagulability in MEN1 has been previously unidentified. Our cohort data suggests a two-fold increase in the incidence of VTE as compared to the general population, with a high risk occurring within the perioperative period. Further mechanistic investigation and validation from other cohorts are needed to confirm the increased prevalence of VTE in this population. (1)Heit, John A., et al. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015 Aug;12(8): 464-474.
format Online
Article
Text
id pubmed-7208645
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72086452020-05-13 SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients? Lee, Maya E Sustache, Yashira M Ortega Agarwal, Sunita Kishore Tepede, Aisha Mandl, Adel Bansal, Rashika Tirosh, Amit Piaggi, Paolo Weinstein, Lee Scott Simonds, William F Blau, Jenny J Endocr Soc Tumor Biology Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder in which patients develop multiple simultaneous hormone-secreting tumors. Most common tumors include: anterior pituitary adenomas (50%), multi-gland parathyroid adenomas (95%), and gastroenteropancreatic neuroendocrine tumors (40-80%). Only rare MEN1 associated glucagonomas (<1%), and ACTH-producing neuroendocrine tumors (<5%) are known to increase risk of hypercoagulability. It is unknown if patients with MEN1 syndrome have increased risk of venous thrombolytic events (VTE), defined as a deep-vein thrombosis and/or pulmonary embolism. Methods: We queried a prospective natural history study of MEN1 patients who tested positive for germline MEN1 mutations (n=287) between 1991-2019 (54 patients on our current protocol were followed before 1991; the earliest was 1971). All lifetime events of VTE were included. Search terms included: DVT, thromb, embol, PE, pulmonary embolism, clot, hematology consult, anticoagulant, coumadin, lovenox, xarelto, warfarin, aspirin, rivaroxaban and apixaban. After initial screening, 10 patients were removed due to insufficient clinical data. Kaplan-Meier analysis was performed to compare age of death between the two cohorts. Results were expressed as mean ± standard deviation. Results: Thirty-four subjects (mean 57.5 years-old, 17 women) were identified with any VTE, yielding a prevalence rate of 13.4%. The incidence of VTE corresponded to 264 events per 100,000 patient-years, which was ~2-fold higher than the estimated annual incidence rate in the general population (104-183/100,000 patient years).(1) Kaplan-Meier analysis revealed no significant difference in survival between the two groups (non-VTE cohort mean 81.1 years ± 2.23; VTE cohort mean 77.4 years ± 3.45; p = 0.96). Thirty-two events occurred during the surveillance period at our institution; 9 individuals had more than one VTE. At the time of VTE, 80% had hyperparathyroidism (mean PTH ± SD; 97.56 pg/mL ± 90.76), 21% had hyperprolactinemia (prolactin 25.7μg/L ± 43.41), 62.5% had hypergastrinemia (mean gastrin 1100.9 pg/mL ± 3127.8), and 84.6% had non-functional pancreatic neuroendocrine tumors. One patient was identified to have a Factor V Leiden mutation, 3 patients had lupus anti-coagulant. Eleven patients experienced events within a post-surgical period of 3 months. Conclusions: Hypercoagulability in MEN1 has been previously unidentified. Our cohort data suggests a two-fold increase in the incidence of VTE as compared to the general population, with a high risk occurring within the perioperative period. Further mechanistic investigation and validation from other cohorts are needed to confirm the increased prevalence of VTE in this population. (1)Heit, John A., et al. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015 Aug;12(8): 464-474. Oxford University Press 2020-05-08 /pmc/articles/PMC7208645/ http://dx.doi.org/10.1210/jendso/bvaa046.672 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Tumor Biology
Lee, Maya E
Sustache, Yashira M Ortega
Agarwal, Sunita Kishore
Tepede, Aisha
Mandl, Adel
Bansal, Rashika
Tirosh, Amit
Piaggi, Paolo
Weinstein, Lee Scott
Simonds, William F
Blau, Jenny
SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
title SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
title_full SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
title_fullStr SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
title_full_unstemmed SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
title_short SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
title_sort sun-124 are venous thromboembolic events increased in men1 patients?
topic Tumor Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208645/
http://dx.doi.org/10.1210/jendso/bvaa046.672
work_keys_str_mv AT leemayae sun124arevenousthromboemboliceventsincreasedinmen1patients
AT sustacheyashiramortega sun124arevenousthromboemboliceventsincreasedinmen1patients
AT agarwalsunitakishore sun124arevenousthromboemboliceventsincreasedinmen1patients
AT tepedeaisha sun124arevenousthromboemboliceventsincreasedinmen1patients
AT mandladel sun124arevenousthromboemboliceventsincreasedinmen1patients
AT bansalrashika sun124arevenousthromboemboliceventsincreasedinmen1patients
AT tiroshamit sun124arevenousthromboemboliceventsincreasedinmen1patients
AT piaggipaolo sun124arevenousthromboemboliceventsincreasedinmen1patients
AT weinsteinleescott sun124arevenousthromboemboliceventsincreasedinmen1patients
AT simondswilliamf sun124arevenousthromboemboliceventsincreasedinmen1patients
AT blaujenny sun124arevenousthromboemboliceventsincreasedinmen1patients